INTEGRA LIFESCIENCES HOLDINGS CORP 8-K

What Happened
Integra LifeSciences Holdings Corporation (IART) announced that Dr. Stuart M. Essig was appointed President and Chief Executive Officer effective May 1, 2026, succeeding Mojdeh Poul, who left as President, CEO and director effective April 30, 2026. Dr. Essig, 64, will continue to serve as Chairman of the Board; he previously served as Integra’s CEO (1997–2012) and Executive Chairman (Feb 2024–Jun 2025). The company also appointed Michael McBreen as Chief Commercial Officer effective May 1, 2026, promoting him from Executive VP, President, Codman Specialty Surgical.

Key Details

• Dr. Essig compensation: $1,075,000 annual base salary; target annual bonus = 125% of base (2026 bonus prorated). One‑time equity: $4.0M in RSUs + $4.0M in stock options. Vesting: 1/3 at 1 year, remaining 2/3 in 24 equal monthly installments.
• Severance/termination: If terminated without cause (non‑CIC) or resigns for good reason, Dr. Essig eligible for 2.0x (base + target bonus) severance, pro‑rata bonus, up to 18 months COBRA, and full accelerated equity vesting (options exercisable up to 5 years). Post‑change‑in‑control severance = 2.99x (base + target bonus).
• Mojdeh Poul separation: Separation agreement effective April 30, 2026; subject to release, she will receive $566,526 (cash‑out of unvested RSUs and pro‑rata 2026 bonus) and up to $25,000 for legal fees, plus any other payments described in her employment agreement.
• Michael McBreen: base salary $660,000; target bonus 90% of base; one‑time Promotion Award valued at $1,000,000 (50% RSUs / 50% options) vesting in three annual installments; eligible for a 2027 annual equity award with target value $2,000,000. Retirement treatment for McBreen’s equity is specified (full vesting if retiring at/after age 64 with six months’ notice).

Why It Matters
This 8‑K documents a top‑level leadership change with continuity: Dr. Essig is a long‑time Integra executive and remains board chair while resuming CEO duties, which may signal strategic continuity to investors. The new executive pay packages include sizable upfront equity awards and defined severance protections, which will affect executive incentives and could have near‑term compensation expense and future dilution implications. The filing also details the departing CEO’s separation payments, which are contingent on a release of claims.